Grazyna D. Szklarz, Ph.D.
Postdoctoral fellow, 1991-92, University of California, San Francisco, California
M.S. in Biology, 1981, Maria Curie-Sklodowska University, Lublin, Poland
Ph.D. in Chemistry, 1991, Clarkson University, Potsdam, New York
Post-doctoral Fellow, 1991-1992, Department of Pediatrics, University of California, San Francisco, CA
Research Associate, 1992-1995, Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ
Assistant Research Scientist, 1995-1997, Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ
Associate Research Scientist, 1998, Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ
Assistant Professor, August 1998-2004, Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV
Associate Professor, July 2004-present, Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV
Structure and function of cytochromes P450
Homology modeling of enzyme structure
Utilization of molecular modeling methods to study protein function
P450-mediated drug metabolism and carcinogenesis
My current research focuses on structure-function relationships of human cytochromes P450 1A1 and 1A2, which play a key role in the metabolic activation of chemical carcinogens and in the metabolism of drugs. The objective of this research is to elucidate the structural basis for the function of these enzymes using a combination of molecular modeling and experimental methods, such as heterologous expression, site-directed mutagenesis and biochemical assays. We apply molecular modeling methods, such as molecular dynamics, to predict product profiles and kinetic constants, as well as NMR techniques, which will help to characterize enzyme-substrate interactions in the active site.
This research lies at the interface between the application of the theory of computational chemistry and the utilization of experimental methods, such as NMR and molecular biology techniques, and has a potential for advancing our understanding of how enzymes activate or deactivate drugs and xenobiotics.
Molecular modeling , homology modeling of proteins
Heterologous expression of mammalian enzymes in E. coli
Protein purification and analysis - chromatography, SDS-PAGE, Western blots, etc.
Enzyme assays, enzyme kinetics - spectroscopic methods, HPLC
Molecular biology - gene cloning and site-directed mutagenesis
Structural basis for functional differences between human cytochromes P450 1A1 and 1A2, 1999- 2000 (WVU Senate Research Grant)
Active site model of cytochromes P450 1A1 and 1A2, 2000-2002 (NIH/NCI)
Structural determinants of P450 1A1 and 1A2 specificity. 2001-2006 (NIH/NCRR)
Cytochrome P450-reductase interactions in the P450 1A subfamily, 2006 (Bridge Grant, WVU HSC)
Cytochrome P450-reductase interactions in P450 1A subfamily, 2007-2010 (NIH/NIGMS)
Huang Q, Deshmukh RS, Ericksen SS, Tu Y, Szklarz GD. 2012. Preferred Binding Orientations of Phenacetin in CYP 1A1 and 1A2 are Associated with Isoform-selective Metabolism. Drug Metab Dispos. 40: 2324–2331.
He X., Wang L., Szklarz G., Bi Y., Ma Q. 2012. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the Nrf2 pathway. J. Pharmacol. Exp.Ther. 342: 81-90.
Rademacher P.M., Woods C.M., Huang Q., Szklarz G.D., Nelson S.D. 2012. Differential oxidation of two thiophene-containing regioisomers to reactive metabolites by cytochrome P450 2C9. Chem Res Toxicol. 25: 895-903.
Huang, Q. and Szklarz, G.D.
2010. Significant Increase in Phenacetin Oxidation upon Leu-382 → Val Substitution in Human Cytochrome P450 1A2. Drug Metab. Disp.
Tu, Y., Deshmukh, R., Sivaneri, M. and Szklarz, G.D
. 2008. The application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants. Drug Metab. Disp.
Ericksen, S.S. and Szklarz, G.D
. 2005. Regiospecificity of human cytochrome P450 1A1-mediated oxidations: the role of steric effects. J. Biomol. Struct. Dyn
Schwarz, D., Kisselev, P., Ericksen, S.S., Szklarz, G.D.,
Honeck, H., Schunck, W.-H., and Roots, I. 2004. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1. Biochem. Pharmacol.,
Liu, J., Ericksen, S.S., Sivaneri, M., Besspiata, D., Fisher, C.W. and Szklarz, G.D.
2004. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch. Biochem. Biophys.,
Liu, J., Ericksen, S.S., Besspiata, D., Fisher, C.W. and Szklarz, G.D.
2003. Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: case of residue 382. Drug Metab. Disp.
and Paulsen, M.D. 2002. Molecular modeling of cytochrome P450 1A1: Enzyme-substrate interactions and substrate binding affinities. J. Biomol. Struct. Dyn. 20: 155-162.
Xue, L., Wang, H.F., Wang, Q., Szklarz, G.D.,
Domanski, T.L., Halpert, J.R. and Correia, M.A. 2001. Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B1 oxidation. Chem. Res. Toxicol.
Graham, S.E. and Paulsen, M.D. 2000. Molecular modeling of mammalian cytochromes P450: application to study enzyme function. In: Vitamins and Hormones
, G. Litwack, ed., Academic Press, vol. 58, pp. 53-86.
Phar 731: Biopharmaceutics and Pharmacokinetics
Phar 779: Drugs Discovery and Development
Phar 780: Introduction to Molecular Modeling
Phar 781: Drug Metabolism
Member of Editorial Board of Drug Metabolism and Disposition
Workshop Presenter for Expanding Your Horizons in Math and Science Conferences organized by AWIS-WV
American Association of Colleges of Pharmacy
American Chemical Society
American Society for Pharmacology and Therapeutics
Association for Women in Science
International Society for the Study of Xenobiotics